Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Polycythemia Vera

Polycythemia

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Myeloproliferative Disorders

Chronic Myeloproliferative Disorders

Pharmaceutical Solutions

All Drugs and Chemicals

Amino Acids

Serine

SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).

SLN124

Placebo

Silence Therapeutics Patient Information

Moshe Talpaz, Dr

Marina Kremyanskaya, Dr

Lindsay Anne Magura Rein, Dr

Maya Fleyhan

Jonathan Lu, Dr

Hanlon Sia, Dr

Sue Yeend

Akash Kalro, Dr

Ashley Ng, Dr

Andrew Perkins, MD

Andrew Perkins, Prof

Indu Raman, Dr

Carolyn Grove, Dr

Desislava Ilieva-Chiviyska, Dr

Anna Filipova

Ivelina Mladenova

Boyan Semov, Dr

Azizan Sharif, Dr

Wong Yih Seong, Dr

Ahlam Naila Kori, Dr

Normala Binti Nordin, Dr

Chew Lee Ping, Dr

Tiong Xun Ting, Dr

V Selvaratnam, Dr

Ong Jiun Jyh, Dr

Veena Selvaratnam, Dr

Ganesh A/L Kasinathan, Dr

Nur Aina Binti Abdul Rohim

Ganesh Kasinathan, Dr

Witold Prejzner, Dr

Sebastian Grosicki, Dr

Michal Mielnik

Marek Hus, Dr

Roza Jerzewska

Kinga Kuzdak

Michal Kwiatek, Dr

Aleksandra Butrym, MD

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Phase 1 is an open-label, dose-finding study. Phase 2 is a randomized, double-blind, placebo-controlled study.

Study to Assess SLN124 in Patients With Polycythemia Vera

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Safety and tolerability will be reported separately following open-label dose escalation phase and double-blind phase

Silence Therapeutics plc

Symptoms and General Pathology

Diseases and Abnormalities at or Before Birth

Syndrome

Thalassemia

beta-Thalassemia

Preleukemia

Myelodysplastic Syndromes

Precancerous Conditions

Anemia

Hemolysis

Anemia, Hemolytic

Anemia, Hemolytic, Congenital

Hemoglobinopathies

Genetic Diseases, Inborn

Beta-thalassemia

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.

safety and tolerability will be reported separately following single-dose administration.

safety and tolerability will be reported separately following multi-dose administration.

Will be reported separately following single-dose and multiple-dose administration.

safety and tolerability will be reported separately following single-dose and multiple-dose administration.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to Assess SLN124 in Patients With Polycythemia Vera	NCT05499013	Polycythemia Ve...	SLN124 Placebo	18 Years -	Silence Therapeutics plc
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome	NCT04718844	Non-transfusion... Low Risk Myelod... Very-Low Risk M...	SLN124 Placebo	18 Years -	Silence Therapeutics plc
Study to Assess SLN124 in Patients With Polycythemia Vera	NCT05499013	Polycythemia Ve...	SLN124 Placebo	18 Years -	Silence Therapeutics plc
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome	NCT04718844	Non-transfusion... Low Risk Myelod... Very-Low Risk M...	SLN124 Placebo	18 Years -	Silence Therapeutics plc

Spots Global Cancer Trial Database for sln124

Every month we try and update this database with for sln124 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sln124

Every month we try and update this database with for sln124 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sln124 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.